DOCSLIB.ORG

ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do Science ANNUAL REPORT 2018 … is at the heart of every- thing we do. DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. € 2.2 BILLION invested in research and development in 2018. Around 52,000 hearts beat for science. Employees in 66 countries share a passion for pushing boundaries and making new discoveries. Since 1668, our name has stood for the positive power of science. Online You can find out what else makes our research hearts beat faster at www.emdgroup.com/en/ annualreport/2018 “ We believe that scientific exploration and responsible entrepreneurship make techno- logical advantages possible that benefit us all.” STEFAN OSCHMANN Chairman of the Executive Board and CEO Key Figures for 2018 GROUP Key figures 1 Change € million 2018 2017 € million in % Net sales 14,836 14,517 319 2.2% Operating result (EBIT)2 1,727 2,423 – 696 – 28.7% Margin (% of net sales)2 11.6% 16.7% EBITDA2 3,528 4,164 – 636 – 15.3% Margin (% of net sales)2 23.8% 28.7% EBITDA pre2 3,800 4,246 – 446 – 10.5% Margin (% of net sales)2 25.6% 29.3% Profit after tax 3,396 2,615 781 29.9% Earnings per share (€) 7.76 5.99 1.77 29.5% Earnings per share pre (€)2 5.10 5.92 – 0.82 – 13.9% Business free cash flow2 2,508 3,193 – 685 – 21.4% 1 Fiscal 2017 has been adjusted, see Note (49) “Effects from new accounting standards and other presentation and measurement changes” in the Notes to the Consolidated Financial Statements. 2 Not defined by International Financial Reporting Standard IFRS( s). GROUP GROUP Net sales EBITDA pre2 € million € million 20181 14,836 20181 3,800 20171 14,517 20171 4,246 2016 15,024 2016 4,490 2015 12,845 2015 3,630 2014 11,363 2014 3,388 1 Excluding the Consumer Health business divested in fiscal 2018. 2 Not defined by International Financial Reporting Standards IFRS( s). Key figure for fiscal 2017 adjusted. Business Sectors Healthcare Life Science Performance Materials 4 HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 Highlights of 2018 February 21 Life Science enhances presence in Asia In 2018, we invested in a cell culture facility in South Korea, a manufacturing and distribution center in India, and a facility to accelerate Mobius® single-use manufacturing in China. With these new locations, an investment of € 40 mil- lion, we are responding to growing demand from the biotech industry in Asia. April 19 Merck KGaA, Darmstadt, Germany, sells Consumer Health We reached an agreement to sell our Con- sumer Health business to Procter & Gamble for a cash purchase price of approximately € 3.4 billion. Consumer Health transferred to P&G on December 1. This is a further step in our strategic orientation toward innovation-driven businesses. May 3 350 years This year offered a good reason to celebrate in Darmstadt together with 900 guests from politics, business and industry. During this an- niversary year, we looked to the future as well as the past. For instance, we opened a new innovation center in Darmstadt that pro- 350 vides more space for smart projects outside of our existing business areas. Throughout years 2018, we also held a number of other anniver- sary events around the world. HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 5 June 20 Partnership to accelerate our CRISPR initiative We announced a partnership with Tongji University in Shanghai. As a member of our CRISPR Core Partnership Program, we will 中国 provide the university exclusive access to our genome-editing technology and comprehensive technical support. June 20 Merck KGaA, Darmstadt, Germany, forms cooperation with Alibaba Health To significantly improve the lives of 40 million patients in China by 2025 is an ambitious goal. We have teamed up with Internet healthcare company Alibaba Health to meet this challenge. The collaboration aims to provide Chinese patients with improved access to healthcare ser- vices via a health platform that will start out by tracking drugs for patients with diabetes, thy- roid disorders and cardiovascular diseases. June 20 New OLED technology center in Shanghai We are complementing our OLED positions in Asia with a new OLED technology center in Shanghai – in addition to the existing ones in Korea and Taiwan. Working as a local partner with our customers, we intend to drive inno- vations forward for the display industry and bring them to market faster. 6 HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 July 3 Transformation program for Performance Materials To secure the future prospects of Performance Materials, we have launched the transfor- mation program Bright Future with the aim of further expanding our position as a leading supplier of solutions for the electronics indus- try. After 2019, the average annual sales growth of Performance Materials is expected to be between 2% and 3% again, with Semiconductor Solutions as a significant driver of this growth. July 17 Research heroes wanted We are launching the “Future Insight Prize”, with an award of up to € 1 million annually for groundbreaking scientific work. Over the next 35 years, we’ll be awarding it to pro - mote innovations in the areas of health, nutri- tion and energy. July 30 FDA agrees to review request for approval of cladribine tablets The U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application for cladribine tablets as a potential treatment for patients with relapsing forms of multiple sclerosis. The FDA is examining whether cladribine tablets, a short-course oral treatment, can be used to treat patients in the United States. The proposed dosing is a maximum of 20 days of treatment over two years. HIGHLIGHTS OF 2018 HIGHLIGHTS OF 2018 7 September 11 Bavencio® in combination with INLY TA ® to combat kidney cancer The phase III JAVELIN Renal 101 study evaluat- ing Bavencio® and Pfizer’s Inlyta® compared with Sutent® as initial therapy for patients with advanced renal cell carcinoma yielded positive top-line results. In February 2019 the FDA granted priority review to this therapy based on these interim results. October 17 From Darmstadt to 90 countries Since October 17, 2018, eight fully automated packaging lines and robotized logistics are up and running in the new packaging center, which covers a total area of 15,000 square meters. Here, medications from our current product portfolio are packaged and shipped to more than 90 countries. The new capacities help address rising patient demand for our primary products Glucophage®, Concor® and Euthyrox® in the therapeutic areas diabetes, cardiovascular diseases and thyroid disorders. Some € 63 million were invested in the con- struction of the new packaging center between 2015 and 2018. November 12 New innovation hub in Southern China We announced the plans to establish a new competence center for innovation in Guangzhou in Southern China scheduled to open September 2019. It will be located in the heart of a large biotechnology park where startups will conduct research in all three of our business sectors. To coincide with this, we will also start our three-month China Accelerator Program in 2019. 8 HIGHLIGHTS OF 2018 TABLE OF CONTENTS MAGAZINE November 19 Collaborate against cancer with Syntropy We want to advance cancer research. To that end, we intend to form a joint venture under the name Syntropy with software company Palantir Technologies. Syntropy will enable research cen- ters to have access to a collaborative techno l- ogy platform to drive forward cancer research, speed up scientific progress and improve peo- ple’s lives. November 20 Fourth place in the Access to Medicine Index This result means that we have maintained our ranking since the index was last published in 2016. We are proud of our efforts to improve access to medicine and thus the health of underserved populations. November 28 Recognized compensation system The European investors federation Better Finance recognized us as the company with the most shareholder-friendly board com- pensation system in the German DAX 30 stock index. We revised this system in the run-up to the 2018 Annual General Meeting. The estab- lishment of objective compensation criteria resulted in improved comprehensibility – now even with a seal of quality. HIGHLIGHTS OF 2018 TABLE OF CONTENTS MAGAZINE 9 Table of Contents Magazine 1. Heartbeats Why science? What fascinates us about it? We wanted to find out – so we followed the passion. Research drives us all 12–17 2. Vibrant China China is on the way to becoming a leading high-tech nation. We intend to take an active role in shaping this transformation with our China strategy. Big plans for China 20–22 The health platform for everyone 22–23 New partner 24–25 CONTENTS MAGAZINE OF TABLE Semiconductors as a new driver of growth 26–27 3. Beyond tomorrow Can pandemics be predicted? How does smartphone glucose monitoring work? Where will our meat come from in the future? How can we better connect re­­searchers with each other? Whoever wants to actively shape the future, needs to ask the right questions. The needle-free sensor 30–31 A platform for the fight against cancer 32–33 Real meat without the side effects 34–35 New heroes wanted 36–37 10 HEARTBEATS HEARTBEATS 1 HEARTBEATS HEARTBEATS 11 Heart beats Why science? What fascinates us about it? Each of us has an answer to that.
Load more

Recommended publications
  • Offizielle Mitteilung Der Schweizer Boerse
    Bekanntmachung auf KeyInvest Änderung der Valorennummer und ISIN der Unilever N.V. Change of the Valor number and ISIN of Unilever N.V. Im Zusammenhang mit der Änderung der Valorennummer und ISIN der Unilever N.V. (Bloomberg Code: UNA NA) wurden die Bedingungen der unten genannten Produkte der UBS AG, per 1. Juli 2019 angepasst. Die detaillierten Informationen befinden sich in der entsprechenden Produktedokumentation (Termsheets). With regard to the change of the Valor number and ISIN of Unilever N.V. (Bloomberg Code: UNA NA) UBS AG will adjust the terms of the following products as of 1st July 2019. Detailed information can be found in the respective product documentation (Termsheets). ISIN Name CH0391674139 6.25% p.a. EUR Kick-In GOAL linked to worst of Henkel / Unilever / Beiersdorf / BASF CH0400505621 6.50% p.a. CHF Kick-In GOAL linked to worst of Unilever / Nestlé / Anheuser-Busch / Danone CH0420778752 5.00% p.a. EUR Kick-In GOAL linked to worst of Carrefour / Danone / Nestlé / Unilever CH0410512831 5.50% p.a. EUR Kick-In GOAL linked to worst of Nestlé / Unilever / Danone / Kellogg CH0426877814 5.50% p.a. CHF Kick-In GOAL linked to worst of Barry Callebaut / Mondelez / Danone / Unilever CH0434742570 5.50% p.a. EUR Kick-In GOAL linked to worst of Beiersdorf / Henkel / LOréal / Unilever CH0456067161 8.00% p.a. EUR Callable Kick-In GOAL linked to worst of adidas / LOréal / Unilever / Carrefour CH0468335655 6.00% p.a. EUR Callable Kick-In GOAL linked to worst of Mondelez / Danone / Unilever CH0472609830 8.00% p.a. EUR Kick-In GOAL linked to worst of Carrefour / Danone / Unilever CH0477599200 8.50% p.a.
    [Show full text]
  • Notice of the Annual Stockholders' Meeting
    OF THE OF on April 27, 2012 NOTICE MEETING OF BAYER AG MEETING OF BAYER ANNUAL STOCKHOLDERS’ STOCKHOLDERS’ ANNUAL Please fill out in block letters Please Surname affix stamp First Name Street and house number Postal code Bayer AG c /o Finger Marketing Services Country Postfach 100538 41405 Neuss E-mail Germany Phone 2 CONTENTS NOTICE OF THE ANNUAL STOCKHOLDERS’ MEETING 2012 NOTICE OF THE ANNUAL STOCKHOLDERS’ MEETING 2012 KEY DATA 23 Contents Key data 2010 2011 Change AGENDA € million € million % Sales 35,088 36,528 + 4.1 1. Presentation of the adopted annual fi nancial 3 EBIT 1 2,730 4,149 + 52.0 statements and the approved consolidated fi nancial EBIT before special items 2 4,452 5,025 + 12.9 statements, the combined management report, the re- EBITDA 3 6,286 6,918 + 10.1 port of the Supervisory Board, the explanatory report by EBITDA before special items 2 7,101 7,613 + 7.2 the Board of Management on takeover-related disclosu- EBITDA margin before special items 4 20.2% 20.8% res, and the proposal by the Board of Management on the Income before income taxes 1,721 3,363 + 95.4 one-time delivery delivery regular one-time delivery delivery regular appropriation of distributable profi t for the fi scal year as an app and on the internet Net income 1,301 2,470 + 89.9 2011, as well as the resolution on the appropriation of Earnings per share (€) 5 1.57 2.99 + 90.4 distributable profi t. Core earnings per share (€) 6 4.19 4.83 + 15.3 2.
    [Show full text]
  • R&D Update Call 2020
    R&D Update Call 2020 Luciano Rossetti, Global Head of Research & Development Rehan Verjee, Head of the Global Innovative Medicine Franchises & President of EMD Serono Joern-Peter Halle, Head of Research Klaus Edvardsen, Head of Oncology Development September 25, 2020 Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any misconceptions of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. 2 Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ materially from such statements.
    [Show full text]
  • Henkel AG & Co. Kgaa
    Second Supplement dated 14 January 2020 to the Prospectus dated 4 July 2019 as supplemented by the First Supplement dated 18 September 2019 This document constitutes a supplement (the "Second Supplement") within the meaning of Article 46(3) of Regulation (EU) 2017/1129 of the European Parliament and the Council of 14 June 2017 (the "Prospectus Regulation") in connection with Article 13 Luxembourg law relating to prospectuses for securities dated 10 July 2005, as amended, (Loi relative aux prospectus pour valeurs mobilières, the "Luxembourg Law 2005"), which implemented Directive 2003/71/EC of the European Parliament and the Council of 4 November 2003, as amended (the "Prospectus Directive") to the base prospectus of Henkel AG & Co. KGaA in respect of non- equity securities within the meaning of Art. 22 No. 6(4) of the Commission Regulation (EC) No. 809/2004 of 29 April 2004, as amended, ("Non-Equity Securities") (the "Debt Issuance Programme Prospectus" or the "Prospectus"). This Second Supplement is supplemental to, and must be read in conjunction with the Debt Issuance Programme Prospectus dated 4 July 2019 as supplemented by the first supplement dated 18 September 2019 (the "First Supplement") (the Prospectus together with the First Supplement, the "Supplemented Prospectus"). Henkel AG & Co. KGaA (Düsseldorf, Federal Republic of Germany) as Issuer EUR 6,000,000,000 Debt Issuance Programme (the "Programme") The Issuer has requested the Luxembourg Commission de Surveillance du Secteur Financier (the "Commission") in its capacity as competent
    [Show full text]
  • Henkel Case A
    A GRAND ENTRANCE? Li Ning’s Emergence as a Global, Chinese Brand CASE DEVELOPMENT CENTRE Henkel Customs Broker Rationalisation This case was prepared by Professor Albert Veenstra and Rebecca Chung, with the assistance of Lukas Lohrer. We would like to thank Tesse Douma at Henkel for his information and opinions. This case is based on field research data. It is written to provide material for class discussion rather than to illustrate either effective or ineffective handling of a management situation. Copyright © 2018 RSM Case Development Centre, Erasmus University. No part of this publication may be copied, stored, transmitted, reproduced or distributed in any form or medium whatsoever without the permission of the copyright owner. Please address all correspondence to [email protected]. Henkel: Customs Broker Rationalisation This case explains the customs broker rationalisation programme for European operations of the German multinational conglomerate Henkel AG & Co. KGaA since 2015. Henkel is a manufacturer of adhesive, beauty care, laundry and home care products with 170 production sites in 57 countries and sales in over 150 countries. The case shows how the company’s Global Customs Management and Export Compliance project team in Amsterdam designed and launched the programme, and invited customs broker candidate firms for a final selection in summer 2016. What should the evaluation criteria be for selecting the right broker? Introduction In Summer 2016, an important recommendation was about to be made by Head of the Global Customs Management and Export Control project unit (hereafter “the Compliance team”) of the multinational conglomerate Henkel AG & Co. KGaA (Henkel). He wanted his management superiors to significantly change the company’s approach towards global trade management.
    [Show full text]
  • Invitation to the Ordinary Annual General Meeting on April 1, 2021 (Virtual Annual General Meeting)
    This English translation is provided for convenience only. The German text shall be the sole legally binding version. Invitation to the Ordinary Annual General Meeting on April 1, 2021 (Virtual Annual General Meeting) Beiersdorf Aktiengesellschaft, Hamburg Wertpapier-Kennnummer 520000 ISIN DE0005200000 HEALING OINTMENT 2 Beiersdorf AG Invitation Beiersdorf Aktiengesellschaft share- holders are hereby invited to attend the Company’s Annual General Meeting to be held on Thursday, April 1, 2021, at 10.30 a.m. (CEST) Against the background of the still ongoing coronavirus pandemic and the importance of protecting all parties involved, this year’s Annual General Meeting will again be held as a virtual meeting without the physical presence of the shareholders or their proxy- holders Overview containing information in accordance with Section 125 of the German Stock Corporation Act (AktG) in conjunction with Table 3 of the Implementing Regulation (EU) 2018/12122 A. Specification of the message 1. Unique identifier of the event: Beiersdorf_AGM_2021 2. Type of message: Notice of Annual General Meeting B. Specification of the issuer 1. ISIN: DE0005200000 2. Name of issuer: Beiersdorf Aktiengesellschaft C. Specification of the meeting 1. Date of the General Meeting: 2021-04-01 2. Time of the General Meeting: 08:30 a.m. UTC [corresponds to 10:30 a.m. CEST] 3. Type of General Meeting: Annual General Meeting 4. Location of the General Meeting: https://www .beiersdorf.com/annual-general-meeting 5. Record Date: 2021-03-10 [Record Date within the meaning of § 123 Abs. 4 AktG and § 18 Abs. 2 of the Articles of Association of Beiersdorf Aktiengesellschaft is March 11, 2021] 6.
    [Show full text]
  • Low Discontinuation Rate and Side-Effect Burden After Switching to Cladribine Tablets: Canadian Experience from the Advevatm Patient Support Program
    Low discontinuation rate and side-effect burden after switching to cladribine tablets: Canadian experience from the advevaTM patient support program Jiwon Oh1, Paul Giacomini2, Virginia Devonshire3, Fraser Clift4, Caroline Lemieux5, Meritxell Sabidó6, Arthur Allignol6, Mark S. Freedman7 1Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, ON, Canada. 2Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. 3Division of Neurology, Department of Medicine, University of British Columbia MS/NMO Center, Vancouver, BC, Canada. 4Department of Neurology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada. 5EMD Inc., Mississauga, Canada; a business of Merck KGaA, Darmstadt, Germany. 6Global Epidemiology Department, Merck KGaA, Darmstadt, Germany. 7Department of Medicine, Division of Neurology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. ACTRIMS-ECTRIMS 2020 Virtual Congress | 11-13 September DISCLOSURES This study was sponsored by EMD Inc., Canada (a business of Merck KGaA, Darmstadt, Germany), who reviewed and provided feedback on the poster. The authors had full control of the poster, and provided their final approval of all content Jiwon Oh has received research support from Biogen-Idec, Roche, and EMD Serono and has received personal compensation for consulting from EMD Serono, Sanofi-Genzyme, Biogen-Idec, Roche, Celgene, and Novartis Paul Giacomini has received research or educational
    [Show full text]
  • Adding Cetuximab to Paclitaxel and Carboplatin for First-Line
    www.nature.com/bjc ARTICLE Clinical Study Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP Gunnar Folprecht1, Karolin Trautmann1, Alexander Stein2, Gerdt Huebner3, Michael Stahl4, Stefan Kasper5, Albrecht Kretzschmar6, Claus-Henning Köhne7, Viktor Grünwald 8,9, Ralf-Dieter Hofheinz10, Katharina Schütte1, Harald Löffler11, Carsten Bokemeyer2, Alwin Krämer12 and Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group BACKGROUND: Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS and RR in unfavourable CUP. METHODS: This open-labelled, multicentre Phase 2 study included patients with unfavourable, untreated adeno- or undifferentiated CUP. Patients were randomised to receive either paclitaxel/carboplatin (group A) or paclitaxel/carboplatin plus cetuximab (group B) every 3 weeks for a maximum of 6 cycles followed by cetuximab maintenance in group B. The primary endpoint was PFS in the two groups. Secondary endpoints were RR, toxicity and overall survival (OS). RESULTS: One-hundred-and-fifty patients were randomised (group A = 72, group B = 78). The median PFS and OS for all patients were 3.8 and 8.1 months (95% confidence interval (CI): 2.9–4.8 and 6.8–9.5). There was no significant difference in PFS (3.7 vs 4.6 months, HR 0.98) or OS (8.1 vs 7.4, HR 1.1) between the two treatment groups.
    [Show full text]
  • Beiersdorf Ag Company Report
    MASTERS IN FINANCE BEIERSDORF AG COMPANY REPORT PERSONAL CARE AND SELF-ADHESIVE/ SEALANT 3 JANUARY 2018 STUDENT: CONSTANTIN FELIX WAGNER [email protected] Stable and solid growth Recommendation: HOLD Vs Previous Recommendation HOLD Achieving growth through two distinct businesses Price Target FY18: 91.35 € Vs Previous Price Target NA€ Price (as of 3-Jan-18) 97.90 € ▪ We recommend holding Beiersdorf AG given our FY price Reuters: Bloomberg: target of EUR 91.35 per share that corresponds to an overall downside potential of -6.69% against the current price level of EUR 52-week range (€) 83.95-91.03 97.90 as of 2nd January 2017. Market Cap (€m) 24,671 Outstanding Shares (m) 252 ▪ Dividends attributable to shareholders resulted to EUR Source: Bloomberg 1.49, what is derived by a payout ratio of 39.4% in FY 2018. This in return led to a net shareholder return of EUR 92.84, what represents a downside potential of -5.17%. ▪ Beiersdorf relevant operating markets will experience modest growth, although the European market showed low growth rates of 2.1% and 3.5% for the personal care and self-adhesive and sealant market respectively. China is expected to continue to Source: Bloomberg be the most growing market for the adhesive and sealants (Values in € millions) 2017 2018E 2019F industry. Revenues 7,056 7,347 7,649 EBITDA 1,279 1.394 1,516 ▪ The worldwide personal e-commerce segment revenue is Net Profit 796 882 974 expected to increase by a CAGR of 19.5% from FY 2017 until FY EPS 3.42 3.79 4.19 P/E 26.6 24.0 21.8 2022.
    [Show full text]
  • Euro Stoxx® Large Index
    EURO STOXX® LARGE INDEX Components1 Company Supersector Country Weight (%) SAP Technology Germany 4.46 ASML HLDG Technology Netherlands 3.95 LINDE Chemicals Germany 3.47 LVMH MOET HENNESSY Personal & Household Goods France 3.31 SANOFI Health Care France 3.03 SIEMENS Industrial Goods & Services Germany 2.65 TOTAL Oil & Gas France 2.44 ALLIANZ Insurance Germany 2.24 UNILEVER NV Personal & Household Goods Netherlands 2.10 L'OREAL Personal & Household Goods France 2.03 AIR LIQUIDE Chemicals France 1.99 IBERDROLA Utilities Spain 1.86 SCHNEIDER ELECTRIC Industrial Goods & Services France 1.75 ENEL Utilities Italy 1.74 BAYER Health Care Germany 1.69 ADIDAS Personal & Household Goods Germany 1.55 BASF Chemicals Germany 1.50 DEUTSCHE TELEKOM Telecommunications Germany 1.46 Kering Retail France 1.32 VINCI Construction & Materials France 1.27 ANHEUSER-BUSCH INBEV Food & Beverage Belgium 1.24 BNP PARIBAS Banks France 1.20 ADYEN Industrial Goods & Services Netherlands 1.20 AIRBUS Industrial Goods & Services France 1.20 DEUTSCHE POST Industrial Goods & Services Germany 1.17 DAIMLER Automobiles & Parts Germany 1.15 DANONE Food & Beverage France 1.12 PHILIPS Health Care Netherlands 1.09 Prosus Technology Netherlands 1.06 AXA Insurance France 1.04 SAFRAN Industrial Goods & Services France 1.02 MUENCHENER RUECK Insurance Germany 1.01 ESSILORLUXOTTICA Health Care France 1.00 INTESA SANPAOLO Banks Italy 0.93 Vonovia SE Real Estate Germany 0.93 INFINEON TECHNOLOGIES Technology Germany 0.90 KONE B Industrial Goods & Services Finland 0.89 AHOLD DELHAIZE Retail
    [Show full text]
  • From Good Intentions to Real Results – Corporate Citizenship of Germany's DAX 30 Companies
    FROM GOOD INTENTIONS TO REAL RESULTS Corporate Citizenship of Germany’s DAX 30 Companies + Relevance: Why is Corporate Citizenship a CEO topic? + Trends: What are current and future expectations regarding Corporate Citizenship? + Current practice: How do DAX 30 companies engage in societal causes? + Good practices: What does good Corporate Citizenship look like? + Advice: How can you revise your own Corporate Citizenship approach? 03 01 EXECUTIVE CONTENTS SUMMARY 01 EXECUTIVE SUMMARY __ PAGE 03 We consider Corporate Citizenship as the contributions of businesses to society through the combination of core business activities, CORPORATE CITIZENSHIP social investment and philanthropy, and __ 02 IN A WORLD OF SOCIETAL CHALLENGES PAGE 06 participation in the public policy process. (World Economic Forum, 2002) 03 METHODOLOGY OF THE STUDY __ PAGE 10 04 CORPORATE CITIZENSHIP OF DAX 30 COMPANIES __ PAGE 13 The world is facing dramatic challenges ranging from social people from both the for-profit and non-profit sectors still INTEGRATED CORPORATE CITIZENSHIP: inequality and climate change to healthcare systems that argue that companies should focus on their business and 05 SCHNEIDER ELECTRIC are stretched to the limit. Recognizing these challenges, limit their social activities to paying taxes and simply making the United Nations with their Sustainable Development donations to Non-Governmental Organizations (NGOs). __ AS GOOD PRACTICE EXAMPLE PAGE 20 Goals (SDGs) are calling upon all members of society to play their part. However, this view is slowly changing in different parts of the world, with new regulations being put in place to encourage With their expertise and resources, companies can play a key and enforce a more active role of companies in addressing __ SUMMARY AND RECOMMENDATIONS PAGE 21 role in addressing these societal challenges: the fact that the societal changes.
    [Show full text]
  • Personal Care an Essential Component of Living
    Personal Care An essential component of living Activity Report 2012 Activity Report 2012 Personal Care - An essential component of living 1 of 35 TABLE OF CONTENTS WELCOME 3 • TECHNICAL REGULATORY 12 INTRODUCTION 4 • LEGAL AFFAIRS 13 KEYNOTE MESSAGE FROM COMMISSIONER BORG 5 • COMMUNICATIONS AND PUBLIC AFFAIRS 14 NEW NAME, NEW LOOK, NEW PLACE 6 EVENTS 2012 15 COSMETICS EUROPE’S ACTIVITIES THE EUROPEAN COSMETICS MARKET 2012 18 • INTERNATIONAL ACTIVITIES 7 STRUCTURE 22 • ALTERNATIVES TO ANIMAL TESTING 8 MEMBERS 23 • SUSTAINABLE DEVELOPMENT 10 STAFF 32 • REACH 10 MISSION AND GOALS 35 • SELF-REGULATION IN ADVERTISING 11 Activity Report 2012 Personal Care - An essential component of living 2 of 35 PERSONAL CARE - AN ESSENTIAL COMPONENT OF LIVING FABIO FRANCHINA COSMETICS EUROPE PRESIDENT One of the most rewarding aspects of the cosmetics industry Operating in a globalising world, our industry represents a to create improved products, while our commitment to acting is the knowledge that it enriches the lives of citizens on wide diversity of players: worldwide operating multinational responsibly ensures we deliver in a socially responsible manner. a daily basis. Virtually every person in Europe uses various companies alongside thousands of small and medium size cosmetics and personal care items every day, be they soaps, companies. They all are driven by the same passion: to bring This approach can only enhance our reputation as an industry toothpastes, deodorants or any of the many other products the best quality to the consumer through creativity and science and as representatives of that industry. Our stakeholders our industry provides. based innovation and to earn and preserve their trust on a daily recognise that we operate as a modern industry should do: we basis.
    [Show full text]